

DAFTAR PUSTAKA

1. Lan FY, Filler R, Mathew S, Buley J, Iliaki E, Bruno-Murtha LA, et al. COVID-19 symptoms predictive of healthcare workers' SARS-CoV-2 PCR results. *PLoS One*. 2020;1–12.
2. Nguyen LH, Drew DA, Graham MS, Joshi AD, Guo CG, Ma W, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. *Lancet Public Heal*. 2020;475–83.
3. Itodo GE, Enitan SS, Oyekale AO, Agunsoye J, Asukwo UF, Enitan CB. COVID-19 among Healthcare Workers : Risk of Exposure , Impacts and Biosafety COVID-19 among Healthcare Workers : Risk of Exposure , Impacts and Biosafety Measures – A Review. *Int J Heal Saf Environ*. 2020;6(4):534–48.
4. Jęskowiak I, Wiatrak B, Grosman-Dziewiszek P, Szeląg A. The incidence and severity of post-vaccination reactions after vaccination against covid-19. *Vaccines*. 2021;5–8.
5. Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. *Nat Med*. 2021;27(5):790–2.
6. Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. *BMJ*. 2021;373:5–11.
7. Redmond SN, Jones LD, Sadri N, Schmotzer C, Navas ME, Zabarsky TF, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated and unvaccinated healthcare personnel in a Veterans Affairs healthcare system. *Infect Control Hosp Epidemiol*. 2020;2:1–2.
8. Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. *Eurosurveillance*. 2021;1–7.
9. Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Assessing

- the Effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 Vaccination in Prevention of Hospitalisations in Elderly and Frail Adults: A Single Centre Test Negative Case-Control Study. *SSRN Electron J*. 2021;5–28.
10. Hairunisa N, Amalia H. Review: penyakit virus corona baru 2019 (COVID-19). *J Biomedika dan Kesehat*. 2020;3(2):90–100.
 11. Chou R, Dana T, Buckley DI, Selph S, Fu R, Totten AM. Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers: A Living Rapid Review. *Ann Intern Med*. 2020;173(2):120–36.
 12. Hassanian-Moghaddam H, Zamani N, Kolahi AA. COVID-19 pandemic, healthcare providers' contamination and death: An international view. *Crit Care*. 2020;24(1):1–2.
 13. Mhango M, Dzobo M, Chitungo I, Dzinamarira T. COVID-19 Risk Factors Among Health Workers: A Rapid Review. *Saf Health Work*. 2020;11(3):262–5.
 14. Abbasi-Oshaghia E, Mirzaeia F, Farahanid F, Khodadadie I, Tayebiniaf H. Diagnosis and treatment of coronavirus disease. *Int J Surg*. 2020;12–5.
 15. Pietrobon AJ, Teixeira FME, Sato MN. Immunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People. *Front Immunol*. 2020 Oct;11:1–18.
 16. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. *N Engl J Med*. 2020;382(17):1653–9.
 17. Sokolowska M, Lukasik ZM, Agache I, Akdis CA, Akdis D, Akdis M, et al. Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). *Allergy*. 2020 Oct;75(10):2445–76.
 18. Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, et al. Complement as a target in COVID-19? *Nat Rev Immunol* [Internet]. 2020;20(6):343–4. Available from: <http://dx.doi.org/10.1038/s41577-020-0320-7>
 19. Mo P, Deng L, Liu X, Gao S, Liang K, Luo M, et al. Risk factors for

- delayed negative conversion of SARS-CoV-2 in patients with COVID-19 pneumonia: A retrospective cohort study. *Epidemiol Infect.* 2020;(May):5–12.
20. Marik P. Evms Critical Care Covid-19 Management Protocol This Is a Steroid Responsive Disease : However , Timing Is Critical. *Evms.* 2020;1–23.
 21. Plotkin SA, Orenstein WA, Offit PA. Plotkin’s Vaccines. In: Elsevier. 2018. p. 136–54.
 22. Singh R, Kang A, Luo X, Jeyanathan M, Gillgrass A, Afkhami S, et al. COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. *FASEB J.* 2021;35(3):19.
 23. Chowdhury MA, Hossain N, Kashem MA, Shahid MA, Alam A. Immune response in COVID-19: A review. *J Infect Public Health.* 2020;13(11):1619–29.
 24. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. *Nat Rev Immunol.* 2020;20(10):615–32.
 25. Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. *Nat Rev Drug Discov* [Internet]. 2020;19(5):305–6. Available from: <http://dx.doi.org/10.1038/d41573-020-00073-5>
 26. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. 2021;325(13):1318–20.
 27. Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. *Front Immunol.* 2019;10:1–13.
 28. Wang F, Kream RM, Stefano GB. An evidence based perspective on mRNA-SARScov-2 vaccine development. *Med Sci Monit.* 2020;26:1–8.
 29. Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A. Opportunities and challenges in the delivery of mrna-based vaccines. *Pharmaceutics.* 2020;12:5–12.
 30. Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. *Vaccines.* 2014;2(3):624–41.

31. Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, et al. Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review). *Int J Mol Med*. 2020;46(1):3–16.
32. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. *Asian Pacific J Allergy Immunol*. 2020;38(1):1–9.
33. Heaton PM. The Covid-19 Vaccine-Development Multiverse. *N Engl J Med*. 2020;383(20):1985–6.
34. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. *JAMA - J Am Med Assoc*. 2021;326(1):35–45.
35. Li Y Der, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. Coronavirus vaccine development: from SARS and MERS to COVID-19. *J Biomed Sci*. 2020;27(1):1–23.
36. Health Public Ontario. Confirmed Cases of COVID-19 Following Vaccination in Ontario. *Public Heal Ontario* [Internet]. 2021;7:1–27. Available from: <https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-epi-confirmed-cases-post-vaccination.pdf?la=en>
37. Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination. *US Dep Heal Hum Serv*. 2021;372:1413–8.
38. Marchi PM, Marrone L, Brasseur L, Bousset L, Webster CP, Destro M, et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infection. *MedRxiv*. 2021;4–12.
39. Madewell ZJ, Yang Y, Jr IML, Halloran ME, Dean NE. Equivalency of Protection from Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis. *medRxiv*. 2020;6:1–13.
40. The Possibility of COVID-19 after Vaccination: Breakthrough Infections

- [Internet]. Centers for Disease Control and Prevention. 2021. p. 1–2. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html>
41. Klompas M. Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination. *Jama*. 2021;15:19–21.
 42. Ke R, Martinez PP, Smith RL, Gibson LL, Chad J. Longitudinal analysis of SARS-CoV-2 vaccine breakthrough infections reveal limited infectious virus shedding and restricted tissue distribution. 2021;3–7.
 43. Gier B de, Andeweg S, Backer JA, Hahné SJM, Hof S van den, Melker HE de, et al. Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), August-September 2021, the Netherlands. *medRxiv* [Internet]. 2021;2–9. Available from: <https://emea.mitsubishielectric.com/ar/products-solutions/factory-automation/index.html>
 44. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels K, et al. The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmission. *medRxiv* [Internet]. 2021;3–5. Available from: <http://medrxiv.org/content/early/2021/09/29/2021.09.28.21264260.abstract>
 45. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *Lancet Infect Dis*. 2021;1–13.
 46. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK : a prospective observational study. *Lancet Infect Dis*. 2021;21:939–49.
 47. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases , hospitalisations , and deaths following a nationwide vaccination campaign in Israel : an observational study using national surveillance data. *Lancet*. 2021;397(10287):1819–29.

48. Agrawal U, Katikireddi SV, Mccowan C, Mulholland RH, Azcoaga-lorenzo A, Amele S, et al. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2 · 57 million people in Scotland (EAVE II): a prospective cohort study. *Lancet Respir.* 2021;1–11.
49. Hippisley-cox J, Coupland CAC, Mehta N, Keogh RH, Diaz-ordaz K, Khunti K, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination : national prospective cohort study. 2021;1–5.
50. Soebandrio A, Kusumaningrum T, Yudhaputri FA, Oktavianthi S, Safari D, Malik SG, et al. COVID-19 prevalence among healthcare workers in Jakarta and neighbouring areas in Indonesia during early 2020 pandemic. *Ann Med* [Internet]. 2021;53(1):1896–904. Available from: <https://doi.org/10.1080/07853890.2021.1975309>
51. Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S. Monitoring Incidence of COVID-19 Cases , Hospitalizations , and Deaths , by. *Cdc Mmwr.* 2021;70(37):1284–90.
52. Al-Kuwari MG, AbdulMalik MA, Al-Nuaimi AA, Abdulmajeed J, Al-Romaihi HE, Semaan S, et al. Epidemiology Characteristics of COVID-19 Infection Amongst Primary Health Care Workers in Qatar: March-October 2020. *Front Public Heal.* 2021;9(May):1–6.
53. Atnafie SA, Anteneh DA, Yimenu DK, Kifle ZD. Assessment of exposure risks to COVID-19 among frontline health care workers in Amhara Region, Ethiopia: A cross-sectional survey. *PLoS One.* 2021;16(4 April):1–14.
54. Hussen H, Aderaw Alemu Z. Risk of COVID-19 Infection and Associated Factors Among Healthcare Workers: A Cross-Sectional Study at Eka Kotebe Treatment Center in Ethiopia. *Int J Gen Med.* 2021;Volume 14:1763–72.
55. El-Raey F, Alboraie M, Youssef N, Yousef A, Abdelmoaty AA, Hassan E, et al. Predictors for severity of sars-cov-2 infection among healthcare workers. *J Multidiscip Healthc.* 2021;14(August):2973–81.
56. Rudberg AS, Havervall S, Månberg A, Jernbom Falk A, Aguilera K, Ng H,

- et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. *Nat Commun.* 2020;11(1):1–8.
57. Singh C, Naik BN, Pandey S, Biswas B, Pati BK, Verma M, et al. Effectiveness of COVID-19 vaccine in preventing infection and disease severity: A case-control study from an Eastern State of India. *Epidemiol Infect.* 2021;149:35–43.
58. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. *Lancet.* 2021;397(10286):1725–35.
59. Wen S, Prasad A, Freeland K, Podury S, Patel J, Subedi R, et al. Clinical characteristics and outcomes of covid-19 in west virginia. *Viruses.* 2021;13(5):1–14.
60. Wenham C, Fernandez M, Corrêa MG, Lotta G, Schall B, Rocha MC, et al. Gender and Race on the Frontline: Experiences of Health Workers in Brazil during the COVID-19 Pandemic. *Soc Polit Int Stud Gender, State Soc.* 2021;5–8.
61. Ya'qoub L, Elgendy IY, Pepine CJ. Sex and gender differences in COVID-19: More to be learned! *Am Hear J Plus Cardiol Res Pract* [Internet]. 2021;3:1–2. Available from: <https://doi.org/10.1016/j.ahjo.2021.100011>
62. Das SK. The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19). *Indian J Clin Biochem* [Internet]. 2020;35(4):385–96. Available from: <https://doi.org/10.1007/s12291-020-00919-0>
63. Díez-Manglano J, Solís-Marquínez MN, García AA, Alcalá-Rivera N, Riesco IM, Aseguinolaza MG, et al. Healthcare workers hospitalized due to COVID-19 have no higher risk of death than general population. Data from the Spanish SEMI-COVID-19 Registry. *PLoS One.* 2021;16(2 February):1–18.
64. The Jakarta Post. Indonesia lost 130 doctors, 92 nurses to COVID-19, medical association says [Internet]. 2020. Available from: <https://www.thejakartapost.com/news/2020/10/05/>

65. Zhang Z, Guo L, Huang L, Zhang C, Luo R, Zeng L, et al. Distinct Disease Severity Between Children and Older Adults With Coronavirus Disease 2019 (COVID-19): Impacts of ACE2 Expression, Distribution, and Lung Progenitor Cells. *Clin Infect Dis*. 2021;4154–65.
66. Cucunawangsih C, Wijaya RS, Lugito NPH, Suriapranata I. Post-vaccination cases of COVID-19 among healthcare workers at Siloam Teaching Hospital, Indonesia. *Int J Infect Dis [Internet]*. 2021;107:268–70. Available from: <https://doi.org/10.1016/j.ijid.2021.05.020>
67. Backer JA, Klinkenberg D, Wallinga J. The incubation period of 2019-nCoV infections among travellers from Wuhan, China. *medRxiv*. 2020;(January):1–6.
68. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, et al. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: A statistical analysis of publicly available case data. *J Clin Med*. 2020;5–8.
69. Liu T, Hu J, Kang M, Lin L, Zhong H XJ. Transmission dynamic of 2019 novel virus (2019-nCoV). *PrePrint*. 2020;5–8.
70. Zaki N, Mohamed EA. The estimations of the COVID-19 incubation period: A scoping reviews of the literature. *J Infect Public Health [Internet]*. 2021;14(5):638–46. Available from: <https://doi.org/10.1016/j.jiph.2021.01.019>
71. Faes C, Abrams S, Van Beekhoven D, Meyfroidt G, Vlieghe E, Hens N. Time between symptom onset, hospitalisation and recovery or death: Statistical analysis of belgian covid-19 patients. *Int J Environ Res Public Health*. 2020;17(20):1–18.
72. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. *N Engl J Med*. 2021;385(16):1474–84.
73. Duarte LF, Gálvez NMS, Iturriaga C, Melo-González F, Soto JA, Schultz BM, et al. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. *Front Immunol*. 2021;12(September):1–13.

74. Baltas I, Free R, Nhs L, Trust F. Post-vaccination COVID-19: A case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals. 2021;8–15.
75. Zhou GW, Zhang W, Dong YC, Huang HD, Hu C, Sun J, et al. Flexible bronchoscopy-induced massive bleeding: A 12-year multicentre retrospective cohort study. *Respirology*. 2016;21(5):927–31.
76. Smith AW, Ph D, Mulholland K. Effectiveness of an Inactivated SARS-CoV-2 Vaccine. *N Engl J Med*. 2021;2021–3.
77. Van Loon N, Verbrugge M, Cartuyvels R, Ramaekers D. Diagnosis of COVID-19 Based on Symptomatic Analysis of Hospital Healthcare Workers in Belgium Observational Study in a Large Belgian Tertiary Care Center during Early COVID-19 Outbreak. *J Occup Environ Med*. 2021;63(1):27–31.
78. Magnavita N, Tripepi G, Di Prinzio RR. Symptoms in health care workers during the covid-19 epidemic. A cross-sectional survey. *Int J Environ Res Public Health*. 2020;17(14):1–15.
79. Zhao X-Y, Xu X-X, Yin H-S, Hu Q-M, Xiong T, Tang Y-Y, et al. Clinical Characteristics of Patients with 2019 Coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. 2020;1–8.
80. Vahey GM, Marshall KE, McDonald E, Martin SW, Tate JE, Midgley CM, et al. Symptom profiles and progression in hospitalized and nonhospitalized patients with coronavirus disease, Colorado, USA, 2020. *Emerg Infect Dis*. 2021;27(2):385–95.
81. Kambhampati, Anita K., Alissa C. O'Halloran, Michael Whitaker SSM. COVID-19 – Associated Hospitalizations Among Health Care Personnel — . 2020;69(43):1–9. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6943e3.htm?s_cid=mm6943e3_w#suggestedcitation
82. Bennasrallah C, Zemni I, Dhouib W, Sriha H, Mezhoud N, Bouslama S, et al. Factors associated with a prolonged negative conversion of viral RNA in patients with COVID-19. *Int J Infect Dis [Internet]*. 2021;105:463–9. Available from: <https://doi.org/10.1016/j.ijid.2021.02.089>

83. Drobnik J, Susło R, Pobrotyn P, Fabich E, Magiera V, Diakowska D, et al. COVID-19 among Healthcare Workers in the University Clinical Hospital in Wrocław, Poland. *Int J Environ Res Public Health*. 2021;18(11):1–13.
84. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *Lancet Infect Dis*. 2022;22(1):43–55.
85. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. *J Infect Public Health* [Internet]. 2020;13(12):1833–9. Available from: <https://doi.org/10.1016/j.jiph.2020.07.014>
86. WHO, Geneva S. Clinical management of severe acute respiratory infection when COVID-19 is suspected [Internet]. 2020. Available from: <https://www.who.int/publications-detail/>
87. Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, et al. Severe obesity is associated with higher in-hospital mortality in a cohort of patients with COVID-19 in the Bronx, New York. *Metabolism*. 2020;2–8.
88. Mehanna O, Askary A El, Ali E, Esawy B El, Fathalla T, Gharib AF. Impact of obesity and its associated comorbid conditions on COVID-19 presentation. *Diabetes, Metab Syndr Obes Targets Ther*. 2021;14:409–15.
89. Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. *Circulation*. 2020;4–6.
90. Caci G, Albini A, Malerba M, Noonan DM, Pochetti P, Polosa R. Covid-19 and obesity: Dangerous liaisons. *J Clin Med*. 2020;9(8):1–12.
91. Yu W, Rohli KE, Yang S, Jia P. Impact of obesity on COVID-19 patients. *J Diabetes Complications* [Internet]. 2021;4–7. Available from: <https://doi.org/10.1016/j.jdiacomp.2020.107817>
92. Rahayu LAD, Admiyanti JC, Khalda YI, Ahda FR, Agistany NFF, Setiawati S, et al. Hipertensi, Diabetes Mellitus, Dan Obesitas Sebagai Faktor Komorbiditas Utama Terhadap Mortalitas Pasien Covid-19: Sebuah

- Studi Literatur. *JIMKI J Ilm Mhs Kedokt Indones*. 2021;9(1):90–7.
93. Albadawy RM, Jadoon BA, Mogahed MM, Ibrahim ME, Essawy TS, Amin AMA, et al. The Impact of Comorbidities on the Outcomes of Egyptian COVID-19 Patients: A Follow-Up Study. *J Environ Public Health*. 2021;5–9.
 94. Kario K, Morisawa Y, Sukonthasarn A, Turana Y, Chia YC, Park S, et al. COVID-19 and hypertension—evidence and practical management: Guidance from the HOPE Asia Network. *J Clin Hypertens*. 2020;22(7):1109–19.
 95. Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. *Int J Infect Dis*. 2020;99:47–56.
 96. Giannouchos T V., Sussman RA, Odriozola JMM, Poulas K, Farsalinos K. Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory–confirmed COVID-19 cases Authors. *medRxiv Prepr [Internet]*. 2020;3–7. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6943e3.htm?s_cid=mm6943e3_w#suggestedcitation
 97. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. *JAMA - J Am Med Assoc*. 2020;323(20):2052–9.
 98. Wang X, Zhang H, Du H, Ma R, Nan Y, Zhang T. Risk Factors for COVID-19 in Patients with Hypertension. *Can J Infect Dis Med Microbiol*. 2021;1–4.
 99. Khedr EM, Daef E, Mohamed-Hussein A, Mostafa EF, Zein M, Hassany SM, et al. Impact of comorbidities on COVID-19 outcome. *medRxiv Prepr Serv Heal Sci [Internet]*. 2020; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34013292> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC8132266>
 100. Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O, et al.

- Outcomes of COVID-19 Patients with Comorbidities in Southwest Nigeria. *PLoS One*. 2021;1–12.
101. Theodoros V, Giannouchos RAS, Odriozola JMM, Poulas K, Farsalinos K. Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory–confirmed COVID-19 cases. *J Manag Dev*. 2020;851–68.
 102. Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, Carl CA, et al. COVID-19 length of hospital stay: A systematic review and data synthesis. *BMC Med*. 2020;1–4.
 103. Vekaria B, Overton C, Wiśniowski A, Ahmad S, Aparicio-Castro A, Curran-Sebastian J, et al. Hospital length of stay for COVID-19 patients: Data-driven methods for forward planning. *BMC Infect Dis*. 2021;21(1):1–15.
 104. Oksuz E, Malhan S, Gonen MS, Kutlubay Z, Keskindemirci Y, Tabak F. COVID-19 healthcare cost and length of hospital stay in Turkey: retrospective analysis from the first peak of the pandemic. *Health Econ Rev*. 2021;11(1):1–12.
 105. Edwards KM. Sparing of Severe Covid-19 in Vaccinated Adolescents. *N Engl J Med*. 2022;127:1–2.
 106. Ramakrishnan M, Subbarayan P. Impact of vaccination in reducing Hospital expenses, Mortality and Average length of stay among COVID-19 patients – a retrospective cohort study from India. *medRxiv*. 2021;5–8.
 107. State W. COVID-19 Cases, Hospitalizations, and Deaths by Vaccination Status. 2021;1–18.
 108. State W. Deaths by Vaccination Status Washington State Department of Health. 2021;1–18.
 109. Wang Z, Liu Y, Wei L, Ji JS, Liu Y, Liu R, et al. What are the risk factors of hospital length of stay in the novel coronavirus pneumonia (COVID-19) patients? A survival analysis in southwest China. *PLoS One*. 2022;17:14–23.
 110. León TM, Dorabawila V, Nelson L, Lutterloh E, Bauer UE, Backenson B. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status

and Previous COVID-19 Diagnosis — California and New York , May – November 2021. 2022;71(4):125–31.

111. Jang SY, Seon JY, Yoon SJ, Park SY, Lee SH, Oh IH. Comorbidities and factors determining medical expenses and length of stay for admitted covid-19 patients in Korea. Risk Manag Healthc Policy. 2021;2021–33.

112. Gonzales K, Roeber J, Kanny D, Tran A, Saiki C, Johnson H, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence. Pubmed [Internet]. 2022;213–6.

Available from: <http://www.ars.usda.gov/Services/docs.%0Ahttp://www.ars.usda.gov/Services/docs.%0Ahttp://apps.nccd.cdc.gov/ardi>. †Additional information available at http://apps.nccd.cdc.gov/dach_ardi/info/methods.aspx. § Available at http://www.cdc.gov/nchs/products/life_tables.

